The Active Ingredient and Mechanism of Action of Laminine
The bioactive peptides present in Laminine are believed to activate dormant stem cells and assist in the utilization of phyto amino acids and marine proteins to repair damaged and aged cells.
By drying the proto-embryonic fluid before the peptides are exhausted, a balanced combination of amino acids, peptides, and growth factors can be provided to humans for building, repairing, and maintaining cells.
The embryo of living creatures receives nutrition with remarkable accuracy through a highly adaptable mechanism devised by nature.
The precise blend of oligopeptides may be seen as building blocks without a bridge or a director.
The role of such a director is fulfilled by a growth factor known as the Fibroblast Growth Factor, or FGF, also a bioactive peptide. FGF is prolific in proto-embryonic liquid as well as the human placenta.
On the 11th day of the incubation cycle of a chicken egg, the chicken tissue shows a steep increase in these bioactive peptides, with the appropriate peptides to form the solid organs and bones. A detailed day-by-day study was performed in 1988.
Discovered only in the seventies, FGF and bioactive peptides are critical in the development of embryos, including humans.
Bioactive peptides are responsible for building the linings in the blood vessels, creating the infrastructure for the nutrients to flow to critical areas of the brain and organs.
Research credits bioactive peptides with the potential to directly affect many neuro disorders because of clear results of the ability of bioactive peptides to affect the growth of neurites.
Neurites are signal senders (Axons) and signal receivers (dendrites) attached to the brain neurons.
Research has also shown clearly that new cell cultures show a dramatic increase in peptide and amino acid uptake in the presence of FGF.
This result gives credence to the hypothesis that embryonic growth is influenced by a very precise mechanism, which combines unique combinations of amino acids, peptides, and FGF.
SOURCE: Laminine Clinical Study